Clinical Trials Browser

Phase 3 × Withdrawn × Recurrence × Clear all

NCT04796922 2022-07-18

To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)

Phase 3 Withdrawn

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT01260103 2017-07-26

Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma

Phase 3 Withdrawn

Recurrence, Optic Nerve Glioma